2023-506375-10-00招募中1 期
A study to test whether multiple doses of BI 456906 have an effect on cardiac safety in people with overweight or obesity.
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 110
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A study to test how well multiple doses of BI 3810477 are tolerated by healthy adults.2024-519327-20-00Boehringer Ingelheim International GmbH48
招募中
1 期
A study to test different doses of BI 764532 in patients with small cell lung cancer and other neuroendocrine tumours that are positive for DLL3.2024-513100-34-00Boehringer Ingelheim International GmbH129
已完成
1 期
A study to find a suitable dose of BI 1821736 and test whether it helps people with advanced cancer2022-502125-17-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.14
已完成
1 期
A study to evaluate the effect of multiple doses of carbamazepine on how long aticaprant (JNJ-67953964) stays in the body (pharmacokinetics) in healthy adults2022-502951-77-00Janssen - Cilag International20
招募中
2 期
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI 1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors2022-503066-74-00Bioinvent International AB84